Antibody Drug Conjugates Market Size & Analysis 2022-2028

Global Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application (Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others), By Technology, By Regional Outlook and Forecast, 2022 - 2028

Published Date: May-2022 | Number of Pages: 188 | Format: PDF | Report ID: KBV-18015

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Antibody Drug Conjugates Market, by Application
1.4.2 Global Antibody Drug Conjugates Market, by Technology
1.4.3 Global Antibody Drug Conjugates Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players

Chapter 4. Global Antibody Drug Conjugates Market by Application
4.1 Global Breast Cancer Market by Region
4.2 Global Blood Cancer Market by Region
4.3 Global Urothelial Cancer & Bladder Cancer Market by Region
4.4 Global Others Market by Region

Chapter 5. Global Antibody Drug Conjugates Market by Technology
5.1 Global Cleavable Linker Market by Region
5.2 Global Non-Cleavable Linker Market by Region
5.3 Global Others Market by Region

Chapter 6. Global Antibody Drug Conjugates Market by Region
6.1 North America Antibody Drug Conjugates Market
6.1.1 North America Antibody Drug Conjugates Market by Application
6.1.1.1 North America Breast Cancer Market by Country
6.1.1.2 North America Blood Cancer Market by Country
6.1.1.3 North America Urothelial Cancer & Bladder Cancer Market by Country
6.1.1.4 North America Others Market by Country
6.1.2 North America Antibody Drug Conjugates Market by Technology
6.1.2.1 North America Cleavable Linker Market by Country
6.1.2.2 North America Non-Cleavable Linker Market by Country
6.1.2.3 North America Others Market by Country
6.1.3 North America Antibody Drug Conjugates Market by Country
6.1.3.1 US Antibody Drug Conjugates Market
6.1.3.1.1 US Antibody Drug Conjugates Market by Application
6.1.3.1.2 US Antibody Drug Conjugates Market by Technology
6.1.3.2 Canada Antibody Drug Conjugates Market
6.1.3.2.1 Canada Antibody Drug Conjugates Market by Application
6.1.3.2.2 Canada Antibody Drug Conjugates Market by Technology
6.1.3.3 Mexico Antibody Drug Conjugates Market
6.1.3.3.1 Mexico Antibody Drug Conjugates Market by Application
6.1.3.3.2 Mexico Antibody Drug Conjugates Market by Technology
6.1.3.4 Rest of North America Antibody Drug Conjugates Market
6.1.3.4.1 Rest of North America Antibody Drug Conjugates Market by Application
6.1.3.4.2 Rest of North America Antibody Drug Conjugates Market by Technology
6.2 Europe Antibody Drug Conjugates Market
6.2.1 Europe Antibody Drug Conjugates Market by Application
6.2.1.1 Europe Breast Cancer Market by Country
6.2.1.2 Europe Blood Cancer Market by Country
6.2.1.3 Europe Urothelial Cancer & Bladder Cancer Market by Country
6.2.1.4 Europe Others Market by Country
6.2.2 Europe Antibody Drug Conjugates Market by Technology
6.2.2.1 Europe Cleavable Linker Market by Country
6.2.2.2 Europe Non-Cleavable Linker Market by Country
6.2.2.3 Europe Others Market by Country
6.2.3 Europe Antibody Drug Conjugates Market by Country
6.2.3.1 Germany Antibody Drug Conjugates Market
6.2.3.1.1 Germany Antibody Drug Conjugates Market by Application
6.2.3.1.2 Germany Antibody Drug Conjugates Market by Technology
6.2.3.2 UK Antibody Drug Conjugates Market
6.2.3.2.1 UK Antibody Drug Conjugates Market by Application
6.2.3.2.2 UK Antibody Drug Conjugates Market by Technology
6.2.3.3 France Antibody Drug Conjugates Market
6.2.3.3.1 France Antibody Drug Conjugates Market by Application
6.2.3.3.2 France Antibody Drug Conjugates Market by Technology
6.2.3.4 Russia Antibody Drug Conjugates Market
6.2.3.4.1 Russia Antibody Drug Conjugates Market by Application
6.2.3.4.2 Russia Antibody Drug Conjugates Market by Technology
6.2.3.5 Spain Antibody Drug Conjugates Market
6.2.3.5.1 Spain Antibody Drug Conjugates Market by Application
6.2.3.5.2 Spain Antibody Drug Conjugates Market by Technology
6.2.3.6 Italy Antibody Drug Conjugates Market
6.2.3.6.1 Italy Antibody Drug Conjugates Market by Application
6.2.3.6.2 Italy Antibody Drug Conjugates Market by Technology
6.2.3.7 Rest of Europe Antibody Drug Conjugates Market
6.2.3.7.1 Rest of Europe Antibody Drug Conjugates Market by Application
6.2.3.7.2 Rest of Europe Antibody Drug Conjugates Market by Technology
6.3 Asia Pacific Antibody Drug Conjugates Market
6.3.1 Asia Pacific Antibody Drug Conjugates Market by Application
6.3.1.1 Asia Pacific Breast Cancer Market by Country
6.3.1.2 Asia Pacific Blood Cancer Market by Country
6.3.1.3 Asia Pacific Urothelial Cancer & Bladder Cancer Market by Country
6.3.1.4 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Antibody Drug Conjugates Market by Technology
6.3.2.1 Asia Pacific Cleavable Linker Market by Country
6.3.2.2 Asia Pacific Non-Cleavable Linker Market by Country
6.3.2.3 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Antibody Drug Conjugates Market by Country
6.3.3.1 China Antibody Drug Conjugates Market
6.3.3.1.1 China Antibody Drug Conjugates Market by Application
6.3.3.1.2 China Antibody Drug Conjugates Market by Technology
6.3.3.2 Japan Antibody Drug Conjugates Market
6.3.3.2.1 Japan Antibody Drug Conjugates Market by Application
6.3.3.2.2 Japan Antibody Drug Conjugates Market by Technology
6.3.3.3 India Antibody Drug Conjugates Market
6.3.3.3.1 India Antibody Drug Conjugates Market by Application
6.3.3.3.2 India Antibody Drug Conjugates Market by Technology
6.3.3.4 South Korea Antibody Drug Conjugates Market
6.3.3.4.1 South Korea Antibody Drug Conjugates Market by Application
6.3.3.4.2 South Korea Antibody Drug Conjugates Market by Technology
6.3.3.5 Singapore Antibody Drug Conjugates Market
6.3.3.5.1 Singapore Antibody Drug Conjugates Market by Application
6.3.3.5.2 Singapore Antibody Drug Conjugates Market by Technology
6.3.3.6 Malaysia Antibody Drug Conjugates Market
6.3.3.6.1 Malaysia Antibody Drug Conjugates Market by Application
6.3.3.6.2 Malaysia Antibody Drug Conjugates Market by Technology
6.3.3.7 Rest of Asia Pacific Antibody Drug Conjugates Market
6.3.3.7.1 Rest of Asia Pacific Antibody Drug Conjugates Market by Application
6.3.3.7.2 Rest of Asia Pacific Antibody Drug Conjugates Market by Technology
6.4 LAMEA Antibody Drug Conjugates Market
6.4.1 LAMEA Antibody Drug Conjugates Market by Application
6.4.1.1 LAMEA Breast Cancer Market by Country
6.4.1.2 LAMEA Blood Cancer Market by Country
6.4.1.3 LAMEA Urothelial Cancer & Bladder Cancer Market by Country
6.4.1.4 LAMEA Others Market by Country
6.4.2 LAMEA Antibody Drug Conjugates Market by Technology
6.4.2.1 LAMEA Cleavable Linker Market by Country
6.4.2.2 LAMEA Non-Cleavable Linker Market by Country
6.4.2.3 LAMEA Others Market by Country
6.4.3 LAMEA Antibody Drug Conjugates Market by Country
6.4.3.1 Brazil Antibody Drug Conjugates Market
6.4.3.1.1 Brazil Antibody Drug Conjugates Market by Application
6.4.3.1.2 Brazil Antibody Drug Conjugates Market by Technology
6.4.3.2 Argentina Antibody Drug Conjugates Market
6.4.3.2.1 Argentina Antibody Drug Conjugates Market by Application
6.4.3.2.2 Argentina Antibody Drug Conjugates Market by Technology
6.4.3.3 UAE Antibody Drug Conjugates Market
6.4.3.3.1 UAE Antibody Drug Conjugates Market by Application
6.4.3.3.2 UAE Antibody Drug Conjugates Market by Technology
6.4.3.4 Saudi Arabia Antibody Drug Conjugates Market
6.4.3.4.1 Saudi Arabia Antibody Drug Conjugates Market by Application
6.4.3.4.2 Saudi Arabia Antibody Drug Conjugates Market by Technology
6.4.3.5 South Africa Antibody Drug Conjugates Market
6.4.3.5.1 South Africa Antibody Drug Conjugates Market by Application
6.4.3.5.2 South Africa Antibody Drug Conjugates Market by Technology
6.4.3.6 Nigeria Antibody Drug Conjugates Market
6.4.3.6.1 Nigeria Antibody Drug Conjugates Market by Application
6.4.3.6.2 Nigeria Antibody Drug Conjugates Market by Technology
6.4.3.7 Rest of LAMEA Antibody Drug Conjugates Market
6.4.3.7.1 Rest of LAMEA Antibody Drug Conjugates Market by Application
6.4.3.7.2 Rest of LAMEA Antibody Drug Conjugates Market by Technology

Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:

Purchase Report

 3600
 4320
 6048

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities